Sunday, March 03, 2019 1:59:38 PM
Don't plan on it. I imagine the company will be quite for a while. Lots of law suits still going on and the stock exchange does not like to loose which they did on this one, so in my opinion if they are smart they will lay low until they have some really good substantial news and let all the other crap going on blow over
Recent IGC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:02:08 PM
- IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference • ACCESS Newswire • 05/15/2026 12:00:00 PM
- IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase • ACCESS Newswire • 04/28/2026 04:15:00 PM
- IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion • ACCESS Newswire • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 08:01:33 PM
- IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia • ACCESS Newswire • 04/20/2026 12:30:00 PM
- IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout • ACCESS Newswire • 04/14/2026 12:30:00 PM
- Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts • ACCESS Newswire • 04/08/2026 04:45:00 PM
- IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease • ACCESS Newswire • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:43:01 PM
- IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness • ACCESS Newswire • 03/30/2026 12:00:00 PM
- IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 • ACCESS Newswire • 03/19/2026 01:00:00 PM
- IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 • ACCESS Newswire • 03/18/2026 01:00:00 PM
- IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research • ACCESS Newswire • 02/26/2026 01:30:00 PM
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets • ACCESS Newswire • 02/24/2026 01:30:00 PM
- IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial • ACCESS Newswire • 02/23/2026 01:30:00 PM
- IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances • ACCESS Newswire • 02/17/2026 01:30:00 PM
- IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets • ACCESS Newswire • 02/12/2026 01:30:00 PM
- IGC Pharma Announces Equity Research Update by Alliance Global Partners • ACCESS Newswire • 02/10/2026 01:30:00 PM
- IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center • ACCESS Newswire • 02/09/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 09:02:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:14 AM
